Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure
- 1 February 2003
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 145 (2) , S51-S54
- https://doi.org/10.1067/mhj.2003.154
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Short-term Intravenous Milrinone for Acute Exacerbation of Chronic Heart FailureA Randomized Controlled TrialJAMA, 2002
- Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patientsJournal of the American College of Cardiology, 2002
- Acute Hemodynamic Effects of Conivaptan, a Dual V 1A and V 2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart FailureCirculation, 2001
- Rationale and design of the OPTIME CHF trial: Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart FailureAmerican Heart Journal, 2000
- Vasopressin: A therapeutic target in congestive heart failure?Journal of Cardiac Failure, 1999
- Diuretics and Risk of Arrhythmic Death in Patients With Left Ventricular DysfunctionCirculation, 1999
- Hormones and Hemodynamics in Heart FailureNew England Journal of Medicine, 1999
- Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD).Circulation, 1990